Speakers 2016
- View more
Presentation
- View more
BELHADJ BRIK Najet
Tunisia
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)
Presentation
-
- View more
-
How to optimize therapy? (chairman)
-
New therapeutic strategies (chairman)
-
How to optimize treatment in G3 patients? (chairman)
Presentation
-
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)
Presentation
-
- View more
-
Special populations (chairman)
Presentation
-
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
Staging of steatosis and fibrosis: liver biopsy or indirect markers?
-
What's new in hepatitis B? (chairman)
Presentation
-
- View more
-
Who to treat? (chairman)
Presentation
-
- View more
- View more
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)
Presentation
-
DI BISCEGLIE Adrian
USA
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
- View more
DI MARTINO Vincent
France
-
Treatment of HCV cirrhosis and transplanted patients: when and how?
-
Special populations (chairman)
Presentation
-
- View more
El RAY Ahmed
Egypt
- View more
- View more
- View more
ESTRABAUD Emilie
France
-
How to optimize the strategy against HCV? (chairman)
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)
Presentation
-
FLISIAK Robert
Poland
-
SOUTH & EAST (chairman)
-
Need to assess HCV resistance profile before the initiation of DAAs therapy?
Presentation
-
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
Presentation
- View more
-
How to optimize treatment in G3 patients? (chairman)
Presentation
-
SOUTH & EAST (chairman)
-
Optimal therapy of chronic hepatitis B (chairman)
Presentation
-
GINES Pere
Spain
-
Management of uninfected and infected ascites in cirrhosis
Presentation
-
- View more
GOURNAY Jérôme
France
-
Clinical applications of HBsAg quantification (chairman)
Presentation
-
- View more
- View more
HORBAN Andrzej
Poland
- View more
-
Clinical applications of HBsAg quantification (chairman)
-
Optimal therapy of chronic hepatitis B (chairman)
Presentation
-
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
Presentation
-
- View more
LEROY Vincent
France
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)
Presentation
-
- View more
-
How to optimize therapy? (chairman)
-
Future therapies for HBV and HDV: what can we expect? (chairman)
Presentation
-
MANNS Michael
Germany
-
Future therapies for HBV and HDV: what can we expect? (chairman)
-
New therapeutic strategies (chairman)
Presentation
- View more
- View more
MATHURIN Philippe
France
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)
Presentation
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
- View more
MOUCARI Rami
United Arab Emirates
- View more
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
- View more
PAGEAUX Georges-Philippe
France
- View more
PAIS Raluca
France
Presentation
-
SOUTH & EAST
Presentation
-
- View more
PIETRANGELO Antonello
Italy
-
Management and treatment of NASH (chairman)
-
Iron and the liver
Presentation
-
-
Who to treat? (chairman)
-
HIV-HCV coinfections (chairman)
Presentation
-
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)
Presentation
-
RATZIU Vlad
France
-
Management and treatment of NASH (chairman)
Presentation
-
- View more
- View more
SALMON Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)
Presentation
-
-
How to optimize the strategy against HCV? (chairman)
Presentation
-
SERFATY Lawrence
France
-
Are DAAs therapies associated with HCV eradication? (chairman)
Presentation
- View more
- View more
SOGNI Philippe
France
- View more
TRAN Albert
France
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)
Presentation
-
- View more
- View more
TSERTSVADZE Tengiz
Georgia
- View more
URBANEK Petr
Czech Republic
VALLA Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)
Presentation
-
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)
Presentation
- View more
YAZDANPANAH Yazdan
France
-
HIV-HCV coinfections
Presentation
-
- View more
ZEUZEM Stefan
Germany
-
Is it useful to detect resistance associated variants?
Presentation
-
- View more
ZOULIM Fabien
France
-
What's new in hepatitis B? (chairman)
-
Need to assess HCV resistance profile before the initiation of DAAs therapy? (chairman)
Presentation
-